Pharmaceuticals, Biotechnology and Life Sciences
AiCuris Anti-infective Cures AG (AiCuris), a company focused to the discovery and development of drugs against infectious diseases, and Hybridize…
The startup company Novel Concepts Medical has announced major breakthrough in its research of COVID-19. Its novel plant-based treatment has…
The next phase of the Company’s strategy is to expand the Group’s capabilities by reinvesting proceeds from the recent sale of shares held in SkinBioTherapeutics plc, which generated approximately £2 million. These funds have provided growth capital to broaden and expand the Group’s sales and marketing team, accelerate new product development, increase marketing spend and explore direct to consumer channels in strategic markets. These funds also allow the Company to invest in acquiring new technologies to create a future pipeline of products. This supplements existing plans for expanding product ranges into sports nutrition (LeanBiome™) and healthy ageing (WellBiome®), extending SlimBiome®, OptiBiome®, and LPLDL® product lines and territories, increasing the number of larger partners, and growing gross profit by moving up the value chain to sell a greater portion of finalised products than functional ingredients.
Biosimilars have the potential to broaden patient access to effective and more affordable treatments and generate healthcare savingsCAMBRIDGE, Mass and…
Medix Biochemica has acquired 100 percent of the shares of myPOLS Biotec GmbH. As a result of the acquisition, Medix…
Sanofi today unveiled a new bold and unifying corporate brand that supports the modernization and transformation the company launched in…
The University of Alabama at Birmingham (UAB) and Mereo BioPharma Group plc (NASDAQ: MREO), today announced top-line data from a Phase 1b/2 clinical trial evaluating alvelestat, a novel, orally active Neutrophil Elastase (NE) inhibitor in hospitalized COVID-19 Respiratory Disease patients.
Novavax Monday said that the European Medicines Agency (EMA) has recommended granting a conditional marketing authorization for its ‘ COVID-19 vaccine.
Sanofi will acquire Amunix for an upfront payment of approximately $1 billion and up to $225 million upon achievement of certain future development milestones. The acquisition supports Sanofi’s efforts to accelerate and expand its contributions to innovative medicines for oncology patients, with approximately 20 molecules currently in development.
Astra Zeneca said Tuesday that Ultomiris regulatory submission has been accepted under FDA Priority Review in the US for adults with generalised myasthenia gravis, based on positive Phase III trial in which Ultomiris significantly improved functional activities as measured by Myasthenia Gravis-Activities of Daily Living Profile.